Effects of Synbiotic Supplementation on Chronic Inflammation and the Gut Microbiota in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study
The aim of this study was to investigate the effects of 24-week synbiotic supplementation on chronic inflammation and the gut microbiota in obese patients with type 2 diabetes. We randomized 88 obese patients with type 2 diabetes to one of two groups for 24 weeks: control or synbiotic (<i>Lact...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-02-01
|
| Series: | Nutrients |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6643/13/2/558 |
| _version_ | 1797412669906485248 |
|---|---|
| author | Akio Kanazawa Masanori Aida Yasuto Yoshida Hideyoshi Kaga Takehiro Katahira Luka Suzuki Shoko Tamaki Junko Sato Hiromasa Goto Kosuke Azuma Tomoaki Shimizu Takuya Takahashi Yuichiro Yamashiro Hirotaka Watada |
| author_facet | Akio Kanazawa Masanori Aida Yasuto Yoshida Hideyoshi Kaga Takehiro Katahira Luka Suzuki Shoko Tamaki Junko Sato Hiromasa Goto Kosuke Azuma Tomoaki Shimizu Takuya Takahashi Yuichiro Yamashiro Hirotaka Watada |
| author_sort | Akio Kanazawa |
| collection | DOAJ |
| description | The aim of this study was to investigate the effects of 24-week synbiotic supplementation on chronic inflammation and the gut microbiota in obese patients with type 2 diabetes. We randomized 88 obese patients with type 2 diabetes to one of two groups for 24 weeks: control or synbiotic (<i>Lacticaseibacillus paracasei</i> strain Shirota (previously <i>Lactobacillus casei</i> strain Shirota) and <i>Bifidobacterium breve</i> strain Yakult, and galactooligosaccharides). The primary endpoint was the change in interleukin-6 from baseline to 24 weeks. Secondary endpoints were evaluation of the gut microbiota in feces and blood, fecal organic acids, high-sensitivity C-reactive protein, lipopolysaccharide-binding protein, and glycemic control. Synbiotic administration for 24 weeks did not significantly affect changes in interleukin-6 from baseline to 24 weeks (0.35 ± 1.99 vs. −0.24 ± 1.75 pg/mL, respectively). Relative to baseline, however, at 24 weeks after synbiotic administration there were positive changes in the counts of <i>Bifidobacterium</i> and total lactobacilli, the relative abundances of <i>Bifidobacterium</i> species such as <i>Bifidobacterium adolescentis</i> and <i>Bifidobacterium pseudocatenulatum</i>, and the concentrations of acetic and butyric acids in feces. No significant changes in inflammatory markers were found in the synbiotic group compared to the control group. However, synbiotic administration at least partially improved the gut environment in obese patients with type 2 diabetes. |
| first_indexed | 2024-03-09T05:06:29Z |
| format | Article |
| id | doaj.art-e62d301fb8384db6adc4754cf4745a4b |
| institution | Directory Open Access Journal |
| issn | 2072-6643 |
| language | English |
| last_indexed | 2024-03-09T05:06:29Z |
| publishDate | 2021-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Nutrients |
| spelling | doaj.art-e62d301fb8384db6adc4754cf4745a4b2023-12-03T12:54:46ZengMDPI AGNutrients2072-66432021-02-0113255810.3390/nu13020558Effects of Synbiotic Supplementation on Chronic Inflammation and the Gut Microbiota in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled StudyAkio Kanazawa0Masanori Aida1Yasuto Yoshida2Hideyoshi Kaga3Takehiro Katahira4Luka Suzuki5Shoko Tamaki6Junko Sato7Hiromasa Goto8Kosuke Azuma9Tomoaki Shimizu10Takuya Takahashi11Yuichiro Yamashiro12Hirotaka Watada13Department of Metabolism & Endocrinology, Graduate School of Medicine, Juntendo University, Tokyo 113-8421, JapanFood Research Department, Yakult Central Institute, Tokyo 186-8650, JapanFood Research Department, Yakult Central Institute, Tokyo 186-8650, JapanDepartment of Metabolism & Endocrinology, Graduate School of Medicine, Juntendo University, Tokyo 113-8421, JapanDepartment of Metabolism & Endocrinology, Graduate School of Medicine, Juntendo University, Tokyo 113-8421, JapanDepartment of Metabolism & Endocrinology, Graduate School of Medicine, Juntendo University, Tokyo 113-8421, JapanDepartment of Metabolism & Endocrinology, Graduate School of Medicine, Juntendo University, Tokyo 113-8421, JapanDepartment of Metabolism & Endocrinology, Graduate School of Medicine, Juntendo University, Tokyo 113-8421, JapanDepartment of Metabolism & Endocrinology, Graduate School of Medicine, Juntendo University, Tokyo 113-8421, JapanDepartment of Metabolism & Endocrinology, Graduate School of Medicine, Juntendo University, Tokyo 113-8421, JapanDepartment of Metabolism & Endocrinology, Graduate School of Medicine, Juntendo University, Tokyo 113-8421, JapanYakult Honsha European Research Center for Microbiology, 9052 Gent-Zwijnaarde, BelgiumProbiotics Research Laboratory, Graduate School of Medicine, Juntendo University, Tokyo 113-8421, JapanDepartment of Metabolism & Endocrinology, Graduate School of Medicine, Juntendo University, Tokyo 113-8421, JapanThe aim of this study was to investigate the effects of 24-week synbiotic supplementation on chronic inflammation and the gut microbiota in obese patients with type 2 diabetes. We randomized 88 obese patients with type 2 diabetes to one of two groups for 24 weeks: control or synbiotic (<i>Lacticaseibacillus paracasei</i> strain Shirota (previously <i>Lactobacillus casei</i> strain Shirota) and <i>Bifidobacterium breve</i> strain Yakult, and galactooligosaccharides). The primary endpoint was the change in interleukin-6 from baseline to 24 weeks. Secondary endpoints were evaluation of the gut microbiota in feces and blood, fecal organic acids, high-sensitivity C-reactive protein, lipopolysaccharide-binding protein, and glycemic control. Synbiotic administration for 24 weeks did not significantly affect changes in interleukin-6 from baseline to 24 weeks (0.35 ± 1.99 vs. −0.24 ± 1.75 pg/mL, respectively). Relative to baseline, however, at 24 weeks after synbiotic administration there were positive changes in the counts of <i>Bifidobacterium</i> and total lactobacilli, the relative abundances of <i>Bifidobacterium</i> species such as <i>Bifidobacterium adolescentis</i> and <i>Bifidobacterium pseudocatenulatum</i>, and the concentrations of acetic and butyric acids in feces. No significant changes in inflammatory markers were found in the synbiotic group compared to the control group. However, synbiotic administration at least partially improved the gut environment in obese patients with type 2 diabetes.https://www.mdpi.com/2072-6643/13/2/558synbioticprobioticgalacto-oligosccharides (GOSs)chronic inflammationgut microbiotatype 2 diabetes |
| spellingShingle | Akio Kanazawa Masanori Aida Yasuto Yoshida Hideyoshi Kaga Takehiro Katahira Luka Suzuki Shoko Tamaki Junko Sato Hiromasa Goto Kosuke Azuma Tomoaki Shimizu Takuya Takahashi Yuichiro Yamashiro Hirotaka Watada Effects of Synbiotic Supplementation on Chronic Inflammation and the Gut Microbiota in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study Nutrients synbiotic probiotic galacto-oligosccharides (GOSs) chronic inflammation gut microbiota type 2 diabetes |
| title | Effects of Synbiotic Supplementation on Chronic Inflammation and the Gut Microbiota in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study |
| title_full | Effects of Synbiotic Supplementation on Chronic Inflammation and the Gut Microbiota in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study |
| title_fullStr | Effects of Synbiotic Supplementation on Chronic Inflammation and the Gut Microbiota in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study |
| title_full_unstemmed | Effects of Synbiotic Supplementation on Chronic Inflammation and the Gut Microbiota in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study |
| title_short | Effects of Synbiotic Supplementation on Chronic Inflammation and the Gut Microbiota in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study |
| title_sort | effects of synbiotic supplementation on chronic inflammation and the gut microbiota in obese patients with type 2 diabetes mellitus a randomized controlled study |
| topic | synbiotic probiotic galacto-oligosccharides (GOSs) chronic inflammation gut microbiota type 2 diabetes |
| url | https://www.mdpi.com/2072-6643/13/2/558 |
| work_keys_str_mv | AT akiokanazawa effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy AT masanoriaida effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy AT yasutoyoshida effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy AT hideyoshikaga effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy AT takehirokatahira effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy AT lukasuzuki effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy AT shokotamaki effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy AT junkosato effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy AT hiromasagoto effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy AT kosukeazuma effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy AT tomoakishimizu effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy AT takuyatakahashi effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy AT yuichiroyamashiro effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy AT hirotakawatada effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy |